Human Trials

Investigator-initiated phase 2 trial to expand clinical evaluation of GKT831 into additional fibrotic disorder

Genkyotex said that US National Institutes of Health (NIH) has awarded an $8.9m grant to Professor Victor Thannickal at the University of Alabama at Birmingham (UAB) to fund a multi-year research program to assess the role of NOX enzymes in idiopathic pulmonary fibrosis (IPF).

Emergent starts phase 1 trial of Zika virus immune globulin therapeutic

Emergent BioSolutions has initiated a phase 1 clinical study to assess the safety and pharmacokinetics of its anti-Zika virus immune globulin ZIKV-IG, which is being developed as a therapeutic intervention against Zika virus disease.

RedHill’s RHB-104 meets primary endpoint in phase III Crohn’s disease study

RedHill Biopharma’s RHB-104 orally-administered antibiotic combination therapy has achieved its primary endpoint and key secondary endpoints in phase III Crohn’s disease study.

Destiny Pharma’s XF-73 succeeds in phase 1 skin irritation study

Destiny Pharma, a UK-based clinical stage biotechnology company, has reported positive data for its synthetic antimicrobial drug XF-73 from a phase 1 skin irritation study.

Takeda’s Alunbrig improves PFS in phase 3 lung cancer trial

Takeda’s lung cancer drug Alunbrig (brigatinib) has significantly improved progression-free survival (PFS) in phase 3 ALTA-1L (ALK in lung cancer trial of AP26113 in 1st line) trial.

Chi-Med starts phase Ib/II trial of sulfatinib in NET and BTC patients

Hutchison China MediTech (Chi-Med) has commenced a phase Ib/II proof-of-concept study in the US to evaluate its small molecule angio-immuno kinase inhibitor sulfatinib in pancreatic neuroendocrine tumors (NET) and biliary tract cancer (BTC).

Leap Therapeutics to evaluate TRX518/avelumab combo for advanced solid tumors

Leap Therapeutics has signed a deal to evaluate its immuno-oncology compound TRX518 in combination with Merck and Pfizer’s avelumab, and chemotherapy for the treatment of advanced solid tumors.

Boehringer, Lilly diabetes drug Tradjenta succeeds in cardiovascular outcome trial

Boehringer Ingelheim and Eli Lilly and Company reported that the CARMELINA cardiovascular outcome trial evaluating their diabetes drug Tradjenta met its primary endpoint.

Pfizer, Lilly’s osteoarthritis pain drug meets co-primary endpoints in phase 3 study

Pfizer and Eli Lilly’s osteoarthritis (OA) pain drug, tanezumab, has met all three co-primary endpoints in a phase 3 study.